- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03360396
Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema (ELEVATE)
August 2, 2023 updated by: Boston Scientific Corporation
A Randomized Controlled Study of PneumRx Endobronchial Coil System Versus Standard-of-Care Medical Management in the Treatment of Subjects With Severe Emphysema
This study will look at outcomes between Endobronchial Coil Treatment and Control groups in patients with severe heterogeneous and or homogeneous emphysema.
Study Overview
Detailed Description
This will be a prospective, multicenter, randomized, controlled study comparing outcomes between the Endobronchial Coil and Control Groups.
Subjects will be block randomized in a Treatment to Control ratio of 2:1.
The randomization will be stratified by site and homogeneous versus heterogeneous emphysema, to support a balance of patients with differing heterogeneity in both the Treatment and Control Groups
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Wien, Austria
- Ludwig Boltzmann Institut Fur COPD und pneumologische Epidemologie
-
-
-
-
-
Grenoble, France
- CHU Grenoble
-
Montpellier, France
- CHU Montpellier
-
Nice, France, CS 51069
- Centre Hospitalier Universitaire de Nice
-
Paris, France
- Hôpital Bichat
-
Reims, France, 51092
- CHU de Reims - Hôpital Maison Blanche
-
Strasbourg, France, 67091
- Nouvel Hopital Civil
-
-
-
-
-
Berlin, Germany
- Charite Berlin - Medizinische Klinik mit Schwerpunkt Infektiologie und Pneumologie
-
Berlin, Germany
- Gemeinschaftskrankenhaus Havelhöhe GmbH
-
Bonn, Germany
- Universitätsklinkum Bonn
-
Essen, Germany
- Ruhrlandklinik Essen
-
Heidelberg, Germany
- Thoraxklinik
-
Hemer, Germany
- Lungenklinik
-
Immenhausen, Germany, 34376
- Lungenfachklinik Immenhausen
-
Immenstädt, Germany
- Klinikverbund Kempten-Oberallgäu
-
Stuttgart, Germany
- Krankenhaus vom Roten Kreuz Bad Cannstatt GmbH
-
-
-
-
-
Firenze, Italy
- Ospedale Careggi
-
-
-
-
-
Groningen, Netherlands, 3150-3610536
- University Medical Center Groningen
-
-
-
-
-
London, United Kingdom
- Royal Brompton Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Read, understood and signed the Informed Consent form
- Meets indications for use per the IFU
- Bilateral heterogeneous and/or homogeneous emphysema
- Post bronchodilator 15% predicted ≤ Forced Expiratory Volume in 1 second (FEV1) ≤ 45% predicted
- Post bronchodilator Residual Volume (RV) ≥ 200% predicted
- Post bronchodilator Total Lung Capacity (TLC) >100% pred.
- Post bronchodilator RV/TLC > 55%
- Dyspnea related to hyperinflation scored ≥ 2 on modified Medical Research Council (mMRC) dyspnea scale despite optimal medical management
- Receiving optimal drug therapy and medical management according to clinical practice.
- Performing regular physical activity, at least 2 times per week
- Stopped smoking as confirmed by carboxyhemoglobin (CoHB)
- 100m ≤ 6 minute walk distance (6MWD) ≤ 450m
- Deemed eligible per Eligibility Review Committee (ERC)
- if treated in France, subject must be entitled to French social security.
Exclusion Criteria:
- Known sensitivity to drugs required for performing bronchoscopy or in whom bronchoscopic procedures are contraindicated
- Evidence of active infection in the lungs
- Hypersensitivity or allergy to nitinol (nickel-titanium) or its constituent metals
- Clinical significant pulmonary fibrosis
- Clinically significant, generalized bronchiectasis
- Clinically significant bleeding disorders
- Patient taking immunosuppressive drugs other than steroids (e.g., for the treatment of cancer, rheumatoid arthritis, autoimmune disease, or prevention of tissue or organ rejection).
- Primary diagnosis of asthma
- Two (2) or more COPD exacerbations in the prior year, or 1 or more COPD exacerbations in the prior 3 months with indication for hospitalization assessment, according to GOLD 2017 recommendations .
- Predominant small airways disease defined as significant bronchiectasis with sputum production (> 2 tablespoons daily) or significant bronchial wall thickening per High Resolution Computed Tomography (HRCT)
- Percent Low Attenuation Area (%LAA) < 20% in the most damaged lobe of either lung.
- Computed Tomography (CT) Imaging consistent with active pulmonary infection, significant interstitial disease or pleural disease
- Severe bullous disease (defined by bulla > 8cm or 1/3 of lung volume, or single bullous defect >8 cm) or predominant paraseptal emphysema [defined by numerous large (>1cm) paraseptal defects in the target lobe comprising of >5% of total lung volume].
- Lung pathology of nodule not proven stable or benign
- Radiographic confirmation of atelectasis or other scarring/fibrosis in areas of intended Coil implant
- Use of more than 20 mg/day prednisolone or equivalent dosage of a different corticosteroid
- Severe pulmonary hypertension (Right Ventricular Systolic Pressure (RVSP) > 50 mm Hg or other signs of Pulmonary Hypertension (PHT) with right ventricular dysfunction)
- Severe hypercapnia (PaCO2 > 55 mmHg on room air) and/or severe hypoxemia (PaO2 < 45mm Hg on room air, High altitude criterion: PaO2 < 30 mm Hg)
- Previous Lung Volume Reduction (LVR) surgery, lung transplantation, lobectomy, LVR devices or other device to treat COPD in either lung.
- Diagnosed with alpha-1 antitrypsin deficiency
- Diffusion Capacity of the lungs for Carbon Monoxide (DLCO) < 20 %
- Significant, recent or unstable cardiac disease defined as severe heart failure (Left Ventricular Ejection Fraction (LVEF) < 45% despite optimal medical management), unstable cardiac arrhythmia or coronary artery disease (angina on activity), or ischemic event in the past 6 months.
- Body Mass Index (BMI) > 30
- Participation in any other clinical Study.
- Subject is pregnant or lactating, or plan to become pregnant within the study timeframe.
- If treated in France, Subject is a "personnel vulnerable" as defined by French Regulation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Endobronchial Coils
Treatment with PneumRx Endobronchial Coil System
|
Endobronchial Coil implants
|
No Intervention: Control
Medically-managed control group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in FEV1 at 6 Months
Time Frame: 6 months
|
Percent change in FEV1
|
6 months
|
Absolute Change in SGRQ Score at 6 Months
Time Frame: 6 months
|
Change in SGRQ score - St. George Respiratory Questionnaire from 0 to 100, higher score indicating more limitations (worse), increase in score indicating worse outcome, decrease in score indicating improvement
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Analyses Post Primary Endpoint
Time Frame: 12 and 36 months
|
Descriptive statistics will summarize effectiveness endpoints at 12 and 36 months for all coil treated subjects in France.
|
12 and 36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Felix Herth, MD,, University Hospital Heidelberg
- Principal Investigator: Arschang Valipour, MD,FCCP,PhD, Nord-Klinik Floridsdorf
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2018
Primary Completion (Actual)
February 26, 2020
Study Completion (Actual)
November 22, 2022
Study Registration Dates
First Submitted
November 22, 2017
First Submitted That Met QC Criteria
November 27, 2017
First Posted (Actual)
December 4, 2017
Study Record Updates
Last Update Posted (Actual)
August 28, 2023
Last Update Submitted That Met QC Criteria
August 2, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTG-004517-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Emphysema
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonarySpain, Germany, Italy, Australia
-
Pulmonx CorporationActive, not recruiting
-
Heidelberg UniversityUnknown
-
Royal Brompton & Harefield NHS Foundation TrustCompletedHeterogeneous EmphysemaUnited Kingdom
-
Aeris TherapeuticsCompleted
-
Pulmonx CorporationCompleted
-
University Medical Center GroningenCompletedEmphysema or COPDNetherlands
-
Aeris TherapeuticsCompleted
-
University Medical Center GroningenRecruitingEmphysema or COPDNetherlands
-
Rabin Medical CenterUnknownPatients With Advanced Homogeneous EmphysemaIsrael
Clinical Trials on Endobronchial Coils
-
Mercy Health OhioStryker NeurovascularUnknown
-
Vanderbilt University Medical CenterStryker NeurovascularActive, not recruiting
-
Kaneka Medical America LLCRecruiting
-
Group of Research in Minimally Invasive TechniquesCompletedPelvic Congestion SyndromeSpain
-
Assistance Publique Hopitaux De MarseilleCompletedHemorrhoidal DiseaseFrance
-
Instituto Ecuatoriano de Enfermedades DigestivasCompleted
-
University of MinnesotaWithdrawn
-
Istanbul UniversityNot yet recruiting
-
Penumbra Inc.CompletedIntracranial AneurysmsFrance
-
London School of Hygiene and Tropical MedicineYunnan InstituteUnknown